Biocept

Biocept

- Model NGS - Next-Gen Sequencing Breast Panel - Liquid Biopsy Biomarker

From

0

Combining Biocept’s Liquid Biopsy biomarker testing expertise with Oncomine from Thermo Fisher Scientific’s next-generation sequencing and decision support resources.

Products Details

  • Exclusive, targeted and actionable
  • Cost effective NGS-based solution
  • Turn-around-time (7-10 days upon receipt of specimen in most cases)
  • Sensitivity: 94.1-100% (MAF ≥0.1%)
  • Raw data available for further research
  • Specimen requirements: 8 mLs of peripheral blood in CEE-SURE™ or EDTA Tube
PD-L1, PR, ER, and AR expression testing available through Target Selector™ Circulating Tumor Cell (CTC) testing.

Customer reviews

No reviews were found for Biocept - Model NGS - Next-Gen Sequencing Breast Panel - Liquid Biopsy Biomarker. Be the first to review!